Chronic Myelogenous Leukemia, Version 1.2014.

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Chronic Myelogenous Leukemia (CML) management relies on monitoring molecular response to Tyrosine Kinase Inhibitor (TKI) therapy.
• Quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to the International Scale (IS) is the gold standard for this monitoring.
• Updated guidelines incorporate specific BCR-ABL1 transcript level milestones for assessing treatment efficacy.

Purpose of the Study:

• To outline the 2014 National Comprehensive Cancer Network (NCCN) guidelines for monitoring CML patients.
• To define molecular response milestones using BCR-ABL1 transcript levels.
• To provide recommendations for adjusting TKI therapy based on QPCR results.

Main Methods:

• Utilizing quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to the International Scale (IS).
• Establishing BCR-ABL1 transcript level thresholds at 3 and 6 months post-treatment initiation.
• Recommending treatment modifications based on adherence to or deviation from these molecular milestones.

Main Results:

• BCR-ABL1 transcript level ≤10% (IS) at 3 and 6 months is a key response milestone.
• Levels >10% (IS) at 3 months prompt consideration of alternative TKI therapy, especially after imatinib treatment.
• Continued monitoring every 3 months via QPCR (IS) is advised for all patients, irrespective of milestone achievement.

Conclusions:

• The 2014 NCCN guidelines emphasize QPCR (IS) for precise molecular monitoring in CML.
• Defined response milestones guide timely therapeutic interventions, including switching TKIs.
• Consistent QPCR monitoring ensures optimal long-term management and improved outcomes for CML patients.